Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Kayexalate

(polystyrene sulfonate)

Phase 2Small molecule

CConcordia Pharmaceuticals Inc., Barbados

1

Indications

1

Total Trials

0

Active Trials

0

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

PseudohypoaldosteronismActive, not recruiting

PseudohypoaldosteronismPhase 2

Active, not recruiting

Clinical

Trials by Indication[1]

Pseudohypoaldosteronism1 trial

Phase II Study of the Pathophysiology and Treatment With Enalapril and Polystyrene Sulfonate for Pseudohypoaldosteronism, Type I

Completed·NNational Center for Research Resources (NCRR)·Phase 2·NCT00004328·1 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

KAYEXALATE

NDA NDA011287

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for polystyrene sulfonate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — polystyrene sulfonate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for polystyrene sulfonate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA011287). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Concordia Pharmaceuticals Inc., Barbados company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CConcordia Pharmaceuticals Inc., Barbados

Related News